Trinity Biotech Plans ADS Ratio Change to Regain Nasdaq Compliance
Event summary
- Trinity Biotech will change its ADS ratio from 1:20 to 1:600 Class A ordinary shares, effective July 24, 2026.
- The move is a reverse split equivalent to 1-for-30, aimed at meeting Nasdaq's $1 minimum bid price requirement.
- ADS holders must exchange 30 old ADSs for 1 new ADS via The Bank of New York Mellon.
- No fractional ADSs will be issued; proceeds from aggregated fractions will be distributed to holders.
The big picture
Trinity Biotech's ADS ratio adjustment reflects a common strategy for companies trading below Nasdaq's minimum price threshold. The move aims to broaden investor access while addressing compliance pressures, but its success hinges on whether the structural change can revive market confidence amid broader challenges in diagnostics and emerging tech sectors.
What we're watching
- Market Reaction
- Whether the ADS ratio change will attract broader investor interest and stabilize trading above $5.
- Compliance Impact
- How quickly Trinity Biotech can regain Nasdaq compliance and avoid delisting risks.
- Strategic Pivot
- The pace at which Trinity Biotech integrates its recent acquisitions into core diagnostics and AI data center cooling businesses.
Related topics